278 related articles for article (PubMed ID: 11967820)
1. The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
Belz GG; Breithaupt-Grögler K; Butzer R; Fuchs W; Hausdorf C; Mang C
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):336-41. PubMed ID: 11967820
[TBL] [Abstract][Full Text] [Related]
2. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Belz GG; Butzer R; Kober S; Mang C; Mutschler E
Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
[TBL] [Abstract][Full Text] [Related]
3. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.
Malerczyk C; Fuchs B; Belz GG; Roll S; Butzer R; Breithaupt-Grögler K; Herrmann V; Magin SG; Högemann A; Voith B; Mutschler E
Br J Clin Pharmacol; 1998 Jun; 45(6):567-73. PubMed ID: 9663812
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
Azizi M; Chatellier G; Guyene TT; Ménard J
J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man.
Fuchs B; Breithaupt-Grögler K; Belz GG; Roll S; Malerczyk C; Herrmann V; Spahn-Langguth H; Mutschler E
J Pharm Pharmacol; 2000 Sep; 52(9):1075-83. PubMed ID: 11045887
[TBL] [Abstract][Full Text] [Related]
9. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens; 2001 Dec; 19(12):2241-50. PubMed ID: 11725169
[TBL] [Abstract][Full Text] [Related]
11. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.
Elmfeldt D; Olofsson B; Meredith P
Blood Press; 2002; 11(5):293-301. PubMed ID: 12458652
[TBL] [Abstract][Full Text] [Related]
12. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
Belz GG; Butzer R; Kober S; Mutschler E
J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
[TBL] [Abstract][Full Text] [Related]
14. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
Elmfeldt D; George M; Hübner R; Olofsson B
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers.
Belz GG; Fuchs B; Malerczyk C; Magin SG; Roll S; Mutschler E
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S45-7. PubMed ID: 9331006
[No Abstract] [Full Text] [Related]
16. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Cardiovasc Pharmacol; 2001 Jul; 38(1):141-8. PubMed ID: 11444497
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
19. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
20. Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
Maillard MP; Mazzolai L; Daven V; Centeno C; Nussberger J; Brunner HR; Burnier M
Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1201-8. PubMed ID: 10619583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
